MEDICATION SHORTAGE

OP
P

Peatness

Guest
1651669363000.png
 
OP
P

Peatness

Guest

 
OP
P

Peatness

Guest

Who benefits from these screening? - I no longer trust the process or the headlines

 
OP
P

Peatness

Guest

Effects of Quercetin on Blood Pressure​

 
OP
P

Peatness

Guest

Photosensitivity with Angiotensin II Receptor Blockers:


Conclusions:
Photosensitivity reactions have been reported with almost all ARBs in VigiBase(®) with a positive disproportionality for irbesartan and losartan. Considering that ARBs share the same chemical structure, which may have the same response to sunlight, it is plausible to consider photosensitivity as a possible class effect. Physicians and patients should be aware of potentially serious photosensitivity reactions related to treatment with ARBs.
 
Last edited by a moderator:
OP
P

Peatness

Guest
Fishy Business : Why Fish Oils Can Do More Harm Than Good by Youri Kruse, Raymond Peat (Foreword), Petr Grúz (Introduction)

1655396967100.png
 
OP
P

Peatness

Guest
Natural products against renin-angiotensin system for antifibrosis therapy

1655406813500.png
 

Attachments

  • Natural products against renin-angiotensin system for antifibrosis therapy.pdf
    1.7 MB · Views: 3
OP
P

Peatness

Guest


1655641593300.png
 
Last edited by a moderator:
OP
P

Peatness

Guest

Magnesium in renal fibrosis

 
OP
P

Peatness

Guest

What is emc?


The electronic medicines compendium (emc) contains up to date, easily accessible information about medicines licensed for use in the UK. emc has more than 14,000 documents, all of which have been checked and approved by either the UK or European government agencies which license medicines. These agencies are the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and the European Medicines Agency (EMA).

emc hosts medicines information for medicines licensed for use in Great Britain (England, Scotland and Wales), as well as UK-wide licensed medicines (Great Britain and Northern Ireland).

The following marketing authorisation codes are applicable for Great Britain and UK-wide licensed medicines:

  • PLGB – Medicine licensed by the MHRA for Great Britain only
  • PL – Medicines licensed by the MHRA for the whole of the United Kingdom

Following Brexit, the European government agency, the European Medicines Agency (EMA), will continue to regulate certain medicines for Northern Ireland. This Northern Ireland-specific medicines information can be found on emc northern ireland (www.emcmedicines.com/en-gb/northernireland)

The medicines regulatory authorities have permitted a transition period for EMA licensed information to be updated to MHRA licensed information. emc therefore continues to hold EMA-approved information during this phased approach to full migration to emc northern ireland.

emc was launched in 1999 and has become an established website, trusted for reliable information about medicines. You can search and view medicine information on emc without the need to register. See the Legal and Privacy Policy for full usage terms.

emc is managed and owned by Datapharm Ltd. We work with pharmaceutical companies, the NHS, and other healthcare organisations to provide good information about medicines.

What does emc contain?


emc contains regulated and approved information on medicines available in the UK

  • Summaries of Product Characteristics (known as SPCs or SmPCs)
  • Patient Information Leaflets (known as PILs, Package Leaflets or PLs)
  • Risk Minimisation Materials (RMMs)
  • Letters to healthcare professionals
  • Live Chat
  • Audio/Video
  • Safety Alerts
  • Product Information

Summaries of Product Characteristics

An SmPC tells healthcare professionals, such as doctors, pharmacists and nurses, how to prescribe and use a medicine correctly. An SmPC is based on clinical trials that a pharmaceutical company has carried out, and gives information about dose, use and possible side effects. An SmPC is always written in a standard format, which is explained in our glossary.

Patient Information Leaflets

A PIL is the leaflet that is included in the pack with a medicine. The PIL is a summary of the SmPC and is written for patients. Our glossary section explains more.

Risk Minimisation Materials

Risk Minimisation Materials are part of a suite of measures that aim to optimise the safe and effective use of a medicine. See the glossary for more information.

Letters to HCPs

Letters to HCPs are direct communications to healthcare professionals to aid education and risk management. Their aim is to ensure the safe and effective use of a marketed medicine.

Live Chat

Live chat functionality is provided by the marketing authorisation holder, or manufacturer of a medicine, for healthcare professionals, and sometimes patients, to contact the company’s Medical Information department with questions about their medicines.

Audio/Video

Audio and video content provides additional information in a user friendly way to promote the safe and effective use of a medicine. They may demonstrate how to administer a medicine or improve the accessibility of the information, such as for the blind or visually impaired.

Safety Alert

Safety alerts are issued by the Regulator and/or marketing authorisation holder and contain important public health messages or safety critical information about a medicine.

Product Information

This is additional information about a product. It may include important information such as about a change of ownership of the medicine, package related information or stock issues.

Where does the information come from?


All the information on emc comes directly from pharmaceutical companies or via the medicines regulator (MHRA or EMA). Over 250 pharmaceutical companies subscribe to emc and so pay Datapharm to publish their information on emc website. This is how the information is approved and added.

  • The pharmaceutical company drafts a Summary of Product Characteristics, Patient Information Leaflet or Risk Materials using the up to date information about their medicine
  • The UK or European medicines licensing agency - the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) - then checks and approves the information
  • The pharmaceutical company publishes the approved SmPC, PIL or risk materials on emc

How is the information updated?

When there is new information about a medicine, or when a new medicine is launched, the pharmaceutical company should update emc within 10 days of the UK or European medicines authority approving the change.

The Latest medicine updates page of the emc website shows you all the new or updated documents that have been published. This page also links to detailed information about the exact changes that have been made.

Who can use emc?


emc can be used by those looking for good quality, up to date information about medicines

  • Healthcare professionals, such as doctors, pharmacists or nurses, use emc to check the latest information about medicines, and to help them prescribe medicines safely.
  • Patients or their carers, check information about their medicines.
  • The general public can find information about medicines they are thinking of taking.

emc is an established website, trusted for reliable information about medicines.
 
Last edited by a moderator:
OP
P

Peatness

Guest

 
EMF Mitigation - Flush Niacin - Big 5 Minerals

Similar threads

Back
Top Bottom